title: [Orthopedic Management of Skeletal Metastases].
abstract: Recent advances in drug therapy for metastatic bone diseases are changing the indications for surgical treatments. Bone modifying agents, including bisphosphonates and denosumab, have reduced skeletal-related events. Meanwhile, novel anticancer drugs that have been developed, especially molecular-targeted drugs, can improve the prognoses of patients with bone metastases, thereby potentially increasing the number of patients who could receive benefits from surgeries for metastases. A multidisciplinary approach and the early involvement of surgeons are required for the application of adequate orthopedic treatments, including braces, rehabilitation, and surgeries for local tumor control, palliative fixation, and spinal decompression.
authors.affiliation: Division of Musculoskeletal Oncology, National Cancer Center Hospital.
authors.forename: Nokitaka
authors.initials: N
authors.lastname: Setsu
authors.forename: Eisuke
authors.initials: E
authors.lastname: Kobayashi
authors.forename: Akira
authors.initials: A
authors.lastname: Kawai
mesh_terms: D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy*; D050723:Fractures, Bone / Q000209:etiology / Q000601:surgery; D006801:Humans; D019637:Orthopedic Procedures; D010146:Pain / Q000209:etiology; D010166:Palliative Care; D012307:Risk Factors